(DLB) Dolby Laboratories - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US25659T1079
Audio Codecs, Video Codecs, Cinema Hardware, Cloud Platform
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.07% |
| Yield on Cost 5y | 1.49% |
| Yield CAGR 5y | 8.73% |
| Payout Consistency | 86.1% |
| Payout Ratio | 34.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 21.6% |
| Value at Risk 5%th | 31.5% |
| Relative Tail Risk | -11.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.75 |
| Alpha | -28.64 |
| CAGR/Max DD | -0.05 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.295 |
| Beta | 0.796 |
| Beta Downside | 0.772 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.20% |
| Mean DD | 10.82% |
| Median DD | 10.58% |
Description: DLB Dolby Laboratories November 04, 2025
Dolby Laboratories (NYSE:DLB) designs and licenses audio- and video-codec technologies-including AAC, HE-AAC, Dolby Atmos, Dolby Vision, DD+, AC-4 and HEVC-and sells premium cinema solutions (Dolby Cinemas) and a SaaS platform (Dolby.io) that powers real-time immersive experiences for live events, streaming, and broadcast. Its product portfolio spans hardware (servers, processors, amplifiers, loudspeakers) and software used by film studios, content creators, post-production houses, broadcasters, and live-entertainment venues worldwide.
Key quantitative signals (as of FY 2023) show total revenue of roughly $1.6 billion, with licensing contributing about 55 % and the newer Dolby.io SaaS business growing at a compound annual rate of ~30 % YoY. The company’s operating margin hovered near 20 %, and its cash conversion cycle is under 45 days, reflecting strong recurring cash flows. Sector-wide, the immersive-media market is projected to expand >10 % CAGR through 2028, driven by rising streaming adoption, 5G rollout, and premium-home-theater upgrades-trends that directly boost demand for Dolby’s codecs and premium cinema offerings.
For a deeper, data-driven look at how Dolby’s growth catalysts compare to peer benchmarks, you might explore the analyst tools on ValueRay to surface additional valuation and risk metrics.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (255.0m TTM) > 0 and > 6% of Revenue (6% = 80.9m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 3.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.45% (prev 60.97%; Δ 9.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 472.2m > Net Income 255.0m (YES >=105%, WARN >=100%) |
| Net Debt (-663.0m) to EBITDA (387.8m) ratio: -1.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (96.8m) change vs 12m ago 0.26% (target <= -2.0% for YES) |
| Gross Margin 88.13% (prev 88.97%; Δ -0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.44% (prev 40.69%; Δ 1.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -20.24 (EBITDA TTM 387.8m / Interest Expense TTM -14.3m) >= 6 (WARN >= 3) |
Altman Z'' 9.83
| (A) 0.29 = (Total Current Assets 1.39b - Total Current Liabilities 437.8m) / Total Assets 3.23b |
| (B) 0.82 = Retained Earnings (Balance) 2.63b / Total Assets 3.23b |
| warn (B) unusual magnitude: 0.82 — check mapping/units |
| (C) 0.09 = EBIT TTM 289.2m / Avg Total Assets 3.18b |
| (D) 4.40 = Book Value of Equity 2.62b / Total Liabilities 595.8m |
| Total Rating: 9.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.54
| 1. Piotroski 5.0pt |
| 2. FCF Yield 7.63% |
| 3. FCF Margin 31.89% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -1.71 |
| 6. ROIC - WACC (= 4.47)% |
| 7. RoE 9.90% |
| 8. Rev. Trend 6.08% |
| 9. EPS Trend 6.99% |
What is the price of DLB shares?
As of December 30, 2025, the stock is trading at USD 65.15 with a total of 439,075 shares traded.
Over the past week, the price has changed by -1.65%, over one month by -2.44%, over three months by -9.57% and over the past year by -15.01%.
Over the past week, the price has changed by -1.65%, over one month by -2.44%, over three months by -9.57% and over the past year by -15.01%.
Is DLB a buy, sell or hold?
Dolby Laboratories has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy DLB.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.5 | 38.9% |
| Analysts Target Price | 90.5 | 38.9% |
| ValueRay Target Price | 64.6 | -0.9% |
DLB Fundamental Data Overview December 25, 2025
Market Cap USD = 6.30b (6.30b USD * 1.0 USD.USD)
P/E Trailing = 25.187
P/E Forward = 15.7233
P/S = 4.6715
P/B = 2.4058
P/EG = 2.0755
Beta = 0.89
Revenue TTM = 1.35b USD
EBIT TTM = 289.2m USD
EBITDA TTM = 387.8m USD
Long Term Debt = 38.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 38.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -663.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.64b USD (6.30b + Debt 38.9m - CCE 701.9m)
Interest Coverage Ratio = -20.24 (Ebit TTM 289.2m / Interest Expense TTM -14.3m)
FCF Yield = 7.63% (FCF TTM 430.3m / Enterprise Value 5.64b)
FCF Margin = 31.89% (FCF TTM 430.3m / Revenue TTM 1.35b)
Net Margin = 18.90% (Net Income TTM 255.0m / Revenue TTM 1.35b)
Gross Margin = 88.13% ((Revenue TTM 1.35b - Cost of Revenue TTM 160.1m) / Revenue TTM)
Gross Margin QoQ = 87.13% (prev 86.06%)
Tobins Q-Ratio = 1.75 (Enterprise Value 5.64b / Total Assets 3.23b)
Interest Expense / Debt = 0.29% (Interest Expense 114.0k / Debt 38.9m)
Taxrate = -19.17% (negative due to tax credits) (-7.99m / 41.7m)
NOPAT = 344.6m (EBIT 289.2m * (1 - -19.17%)) [negative tax rate / tax credits]
Current Ratio = 3.17 (Total Current Assets 1.39b / Total Current Liabilities 437.8m)
Debt / Equity = 0.01 (Debt 38.9m / totalStockholderEquity, last quarter 2.62b)
Debt / EBITDA = -1.71 (Net Debt -663.0m / EBITDA 387.8m)
Debt / FCF = -1.54 (Net Debt -663.0m / FCF TTM 430.3m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.90% (Net Income 255.0m / Total Assets 3.23b)
RoE = 9.90% (Net Income TTM 255.0m / Total Stockholder Equity 2.58b)
RoCE = 11.05% (EBIT 289.2m / Capital Employed (Equity 2.58b + L.T.Debt 38.9m))
RoIC = 13.37% (NOPAT 344.6m / Invested Capital 2.58b)
WACC = 8.90% (E(6.30b)/V(6.34b) * Re(8.95%) + D(38.9m)/V(6.34b) * Rd(0.29%) * (1-Tc(-0.19)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 75.88% ; FCFE base≈377.1m ; Y1≈397.4m ; Y5≈468.4m
Fair Price DCF = 114.9 (DCF Value 6.96b / Shares Outstanding 60.6m; 5y FCF grow 5.89% → 3.0% )
EPS Correlation: 6.99 | EPS CAGR: -0.53% | SUE: 2.26 | # QB: 1
Revenue Correlation: 6.08 | Revenue CAGR: -3.55% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.050 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-09-30): EPS=4.26 | Chg30d=+0.002 | Revisions Net=+1 | Growth EPS=+0.5% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.60 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+3.2%
P/E Trailing = 25.187
P/E Forward = 15.7233
P/S = 4.6715
P/B = 2.4058
P/EG = 2.0755
Beta = 0.89
Revenue TTM = 1.35b USD
EBIT TTM = 289.2m USD
EBITDA TTM = 387.8m USD
Long Term Debt = 38.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 38.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -663.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.64b USD (6.30b + Debt 38.9m - CCE 701.9m)
Interest Coverage Ratio = -20.24 (Ebit TTM 289.2m / Interest Expense TTM -14.3m)
FCF Yield = 7.63% (FCF TTM 430.3m / Enterprise Value 5.64b)
FCF Margin = 31.89% (FCF TTM 430.3m / Revenue TTM 1.35b)
Net Margin = 18.90% (Net Income TTM 255.0m / Revenue TTM 1.35b)
Gross Margin = 88.13% ((Revenue TTM 1.35b - Cost of Revenue TTM 160.1m) / Revenue TTM)
Gross Margin QoQ = 87.13% (prev 86.06%)
Tobins Q-Ratio = 1.75 (Enterprise Value 5.64b / Total Assets 3.23b)
Interest Expense / Debt = 0.29% (Interest Expense 114.0k / Debt 38.9m)
Taxrate = -19.17% (negative due to tax credits) (-7.99m / 41.7m)
NOPAT = 344.6m (EBIT 289.2m * (1 - -19.17%)) [negative tax rate / tax credits]
Current Ratio = 3.17 (Total Current Assets 1.39b / Total Current Liabilities 437.8m)
Debt / Equity = 0.01 (Debt 38.9m / totalStockholderEquity, last quarter 2.62b)
Debt / EBITDA = -1.71 (Net Debt -663.0m / EBITDA 387.8m)
Debt / FCF = -1.54 (Net Debt -663.0m / FCF TTM 430.3m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.90% (Net Income 255.0m / Total Assets 3.23b)
RoE = 9.90% (Net Income TTM 255.0m / Total Stockholder Equity 2.58b)
RoCE = 11.05% (EBIT 289.2m / Capital Employed (Equity 2.58b + L.T.Debt 38.9m))
RoIC = 13.37% (NOPAT 344.6m / Invested Capital 2.58b)
WACC = 8.90% (E(6.30b)/V(6.34b) * Re(8.95%) + D(38.9m)/V(6.34b) * Rd(0.29%) * (1-Tc(-0.19)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 75.88% ; FCFE base≈377.1m ; Y1≈397.4m ; Y5≈468.4m
Fair Price DCF = 114.9 (DCF Value 6.96b / Shares Outstanding 60.6m; 5y FCF grow 5.89% → 3.0% )
EPS Correlation: 6.99 | EPS CAGR: -0.53% | SUE: 2.26 | # QB: 1
Revenue Correlation: 6.08 | Revenue CAGR: -3.55% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.050 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-09-30): EPS=4.26 | Chg30d=+0.002 | Revisions Net=+1 | Growth EPS=+0.5% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.60 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+3.2%
Additional Sources for DLB Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle